DEFINITIVE PROXY STATEMENT

Company

BIOCRYST PHARMACEUTICALS INC

Filed

May 10, 2018

Period of Report

June 20, 2018

Accession Number

0001171843-18-003822

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →